72F fusion protein

From Wikipedia, the free encyclopedia

Jump to: navigation, search

72F fusion protein is a candidate tuberculosis vaccine created by Statens Serum Institut (SSI). The 72F fusion protein is composed of the Rv0125 and Rv1196 proteins derived from Mycobacterium tuberculosis. Phase I clinical trials were completed in 2005 and Phase II trials are awaited.

See also [edit]

Fusion protein

References [edit]

Kaufmann SHE, McMichael AJ (2005). "Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis". Nature Med 11 (4 suppl): S33–S44. doi:10.1038/nm1221. PMID 15812488. Retrieved 2006-04-30.

Artificial induction of immunity / Immunization: Vaccines, Vaccination, and Inoculation (J07)

Development

Classes

Administration

Global:
USA:

Vaccines

Bacterial	Anthrax Brucellosis Cholera^# Diphtheria^# Hib^# Meningococcus^# MeNZB NmVac4-A/C/Y/W-135 NmVac4-A/C/Y/W-135 - DT Pertussis^# Plague Pneumococcal^# PCV PPSV Tetanus^# Tuberculosis BCG^# Typhoid^# Ty21a ViCPS Typhus combination: DTwP/DTaP

Viral	Adenovirus Flu^# H1N1 (Pandemrix) LAIV Hepatitis A^# Hepatitis B^# HPV Cervarix Gardasil Japanese encephalitis^# Measles^# Mumps^# Mumpsvax Polio^# Sabin Salk Rabies^# Rotavirus^# Rubella^# Smallpox Dryvax Tick-borne encephalitis Varicella zoster chicken pox^# shingles Yellow fever^# combination: MMR MMRV research: Cytomegalovirus Epstein–Barr Hepatitis C HIV

Protozoan	Malaria Trypanosomiasis

Helminthiasis	Hookworm Schistosomiasis

Other	Cancer vaccines ALVAC-CEA Hepatitis B^# HPV (Cervarix · Gardasil) NicVAX TA-CD TA-NIC

Controversy

See also

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

gr+f/gr+a (t)/gr-p (c)/gr-o

drug (J1p, w, n, m, vacc)

virs(prot)/clss

cutn/syst (hppv/hiva, infl/zost/zoon)/epon

drug (dnaa, rnaa, rtva, vacc)

This immunology article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wikipedia.org/w/index.php?title=72F_fusion_protein&oldid=525873578"